Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazufloxacin Mesilate Ear Drops in CSOM
NCT03675841Phase 1Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pazufloxacin in chronic suppurative otitis media (CSOM) (4 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 2 days. Status: unknown.
02
Drugs
pazufloxacin
03
Conditions
chronic suppurative otitis media (CSOM)
Beyond the preview
Go deeper on NCT03675841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675841.